# Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen

> **NCT04502069** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **RedHill Biopharma Limited**

## Conditions studied

- COVID-19
- Lung Infection

## Interventions

- **DRUG:** Opaganib

## Key facts

- **NCT ID:** NCT04502069
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-08
- **Primary completion:** 2021-02
- **Final completion:** 2021-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** To be replaced with a randomized placebo-controlled study.
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04502069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04502069, "Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04502069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*